Vicore Pharma Holding AB
STO:VICO
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
6.9665
23.3
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one VICO stock under the Base Case scenario is 2.94 SEK. Compared to the current market price of 7.91 SEK, Vicore Pharma Holding AB is Overvalued by 63%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Vicore Pharma Holding AB
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for VICO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Vicore Pharma Holding AB
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Vicore Pharma Holding AB
Balance Sheet Decomposition
Vicore Pharma Holding AB
Current Assets | 478.2m |
Cash & Short-Term Investments | 466.4m |
Receivables | 1.6m |
Other Current Assets | 10.1m |
Non-Current Assets | 565k |
PP&E | 10k |
Intangibles | 555k |
Current Liabilities | 39.9m |
Accounts Payable | 18.2m |
Accrued Liabilities | 17.1m |
Other Current Liabilities | 4.7m |
Non-Current Liabilities | 3.8m |
Other Non-Current Liabilities | 3.8m |
Earnings Waterfall
Vicore Pharma Holding AB
Revenue
|
104.2m
SEK
|
Operating Expenses
|
-329.8m
SEK
|
Operating Income
|
-225.6m
SEK
|
Other Expenses
|
25.5m
SEK
|
Net Income
|
-200.1m
SEK
|
Free Cash Flow Analysis
Vicore Pharma Holding AB
SEK | |
Free Cash Flow | SEK |
VICO Profitability Score
Profitability Due Diligence
Vicore Pharma Holding AB's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Vicore Pharma Holding AB's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
VICO Solvency Score
Solvency Due Diligence
Vicore Pharma Holding AB's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
Vicore Pharma Holding AB's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VICO Price Targets Summary
Vicore Pharma Holding AB
According to Wall Street analysts, the average 1-year price target for VICO is 29.65 SEK with a low forecast of 15.15 SEK and a high forecast of 40.86 SEK.
Dividends
Current shareholder yield for VICO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
VICO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2015-12-10. The firm's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The firm is a wholly owned subsidiary of Mintage Scientific AB.
Contact
IPO
Employees
Officers
The intrinsic value of one VICO stock under the Base Case scenario is 2.94 SEK.
Compared to the current market price of 7.91 SEK, Vicore Pharma Holding AB is Overvalued by 63%.